US EditionAntengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
Antengene receives $80 million upfront and may earn over $1.1 billion in milestones and royalties as UCB advances ATG-201 for autoimmune diseases globally.
- On March 3, 2026, Antengene granted UCB a worldwide exclusive license to develop, manufacture, and commercialize ATG-201, announced from Hong Kong and Brussels.
- Antengene said the agreement lets it complete first-in-human phase 1 studies in two jurisdictions and transfer further ATG-201 development to UCB, with clinical trial applications planned in China and Australia in Q1 2026.
- Technically, ATG-201 employs the AnTenGager platform's steric-hindrance masking and bivalent CD19 binding, gating CD3 binding to reduce cytokine release syndrome and T cell exhaustion risks.
- The deal makes Antengene eligible for over USD 1.1 billion in success-based milestones while receiving USD 80 million upfront and near-term payments, with 9 pipeline products in R&D.
- Antengene will host a conference call and webcast at 9:00 a.m., with HKT sessions at 10:00 p.m. on Wednesday, March 4, 2026.
42 Articles
42 Articles
The Courier-Tribune
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.Antengene will receive USD 80 million of upfront and near-term milestone payments, and is eligible to receive…
UCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager deal - European Biotechnology Magazine
UCB is adding a new kind of immune-cell weapon to its immunology arsenal. The Belgian biopharma said it has struck a global licensing deal with Hong Kong–based Antengene for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) designed to deplete B cells; an approach that has long been validated in autoimmune disease, but is now being re-engineered with next-generation biologics that promise deeper, more durable effects. The post UCB licenses Ant…
07:58 Belgian biotech company UCB is acquiring the rights to one of the research programs from Chinese company Antengene. UCB calls it a new class of drugs and "potential disruption" in the treatment...
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
